1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Insomnia - Pipeline Review, H1 2016

Insomnia - Pipeline Review, H1 2016

  • May 2016
  • -
  • Global Markets Direct
  • -
  • 88 pages

Insomnia - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Insomnia - Pipeline Review, H1 2016’, provides an overview of the Insomnia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Insomnia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Insomnia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Insomnia
- The report reviews pipeline therapeutics for Insomnia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Insomnia therapeutics and enlists all their major and minor projects
- The report assesses Insomnia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Insomnia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Insomnia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Insomnia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Insomnia - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Insomnia Overview 9
Therapeutics Development 10
Pipeline Products for Insomnia - Overview 10
Pipeline Products for Insomnia - Comparative Analysis 11
Insomnia - Therapeutics under Development by Companies 12
Insomnia - Therapeutics under Investigation by Universities/Institutes 13
Insomnia - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Insomnia - Products under Development by Companies 17
Insomnia - Products under Investigation by Universities/Institutes 18
Insomnia - Companies Involved in Therapeutics Development 19
Eisai Co., Ltd. 19
Evotec AG 20
Grupo Ferrer Internacional, S.A. 21
Heptares Therapeutics Limited 22
Intec Pharma ltd. 23
Intra-Cellular Therapies, Inc. 24
Johnson and Johnson 25
Merck and Co., Inc. 26
Neurim Pharmaceuticals Ltd 27
Novartis AG 28
Reviva Pharmaceuticals Inc. 29
Shionogi and Co., Ltd. 30
Takeda Pharmaceutical Company Limited 31
Insomnia - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 40
CB-2810 - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
Drugs to Inhibit Angiotensin II Receptor Type 1 for Insomnia - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
EVT-201 - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
HTL-6641 - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
ITI-007 - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
JNJ-42847922 - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
LASSBio-785 - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
LASSBio-786 - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
lemborexant - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
lorediplon - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
MK-8133 - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
NEO-1940 - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
piromelatine - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
ramelteon - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
S-117957 - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
Small Molecule for Obesity and Insomnia - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
Small Molecule to Inhibit OX2R for Insomnia - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
UCM-765 - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
zaleplon - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
zolpidem tartrate - Drug Profile 63
Product Description 63
Mechanism of Action 63
RandD Progress 63
Insomnia - Recent Pipeline Updates 64
Insomnia - Dormant Projects 75
Insomnia - Discontinued Products 78
Insomnia - Product Development Milestones 80
Featured News and Press Releases 80
Feb 01, 2016: Minerva Neurosciences Announces Top Line Data From MIN-202 Phase I Clinical Study in Japanese Patients 80
Jan 11, 2016: Minerva Neurosciences Announces Favorable Top Line Results From MIN-202 Phase 2A Clinical Trial in Insomnia Disorder 80
Dec 16, 2015: Intec Pharma Further Expands Intellectual Property with a New Patent for the Accordion Pill Zaleplon in Europe 81
Dec 09, 2015: Minerva Provides Year-End Update on Clinical Trial With Central Nervous System Product Candidate MIN-202 81
Sep 24, 2015: Minerva Neurosciences Provides Update on Clinical Development Program With MIN-202, Selective Orexin-2 Receptor Antagonist 82
Jul 14, 2015: Ferrer initiates phase IIa clinical study of Lorediplon in patients with insomnia 83
Jun 16, 2015: Minerva Neurosciences Provides Update on MIN-202, Selective Orexin-2 Receptor Antagonist 83
Jan 21, 2015: Minerva Neurosciences Reports Positive Phase 1 Data With MIN-202, Selective Orexin-2 Antagonist for Treatment of Sleep Disorders Including Primary and Comorbid Insomnia 84
Dec 10, 2014: Eisai Demonstrates Efficacy Of Investigational Dual Orexin Receptor Antagonist E2006 In Sleep Initiation And Maintenance 85
Sep 22, 2014: Minerva Neurosciences Announces Completion of FDA Review of Investigational New Drug Application for MIN-202 and Plans for First U.S.-Based Clinical Trial 86
Appendix 87
Methodology 87
Coverage 87
Secondary Research 87
Primary Research 87
Expert Panel Validation 87
Contact Us 87
Disclaimer 88

List of Tables
Number of Products under Development for Insomnia, H1 2016 10
Number of Products under Development for Insomnia - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Number of Products under Investigation by Universities/Institutes, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 14
Comparative Analysis by Clinical Stage Development, H1 2016 15
Comparative Analysis by Early Stage Development, H1 2016 16
Products under Development by Companies, H1 2016 17
Products under Investigation by Universities/Institutes, H1 2016 18
Insomnia - Pipeline by Eisai Co., Ltd., H1 2016 19
Insomnia - Pipeline by Evotec AG, H1 2016 20
Insomnia - Pipeline by Grupo Ferrer Internacional, S.A., H1 2016 21
Insomnia - Pipeline by Heptares Therapeutics Limited, H1 2016 22
Insomnia - Pipeline by Intec Pharma ltd., H1 2016 23
Insomnia - Pipeline by Intra-Cellular Therapies, Inc., H1 2016 24
Insomnia - Pipeline by Johnson and Johnson, H1 2016 25
Insomnia - Pipeline by Merck and Co., Inc., H1 2016 26
Insomnia - Pipeline by Neurim Pharmaceuticals Ltd, H1 2016 27
Insomnia - Pipeline by Novartis AG, H1 2016 28
Insomnia - Pipeline by Reviva Pharmaceuticals Inc., H1 2016 29
Insomnia - Pipeline by Shionogi and Co., Ltd., H1 2016 30
Insomnia - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 31
Assessment by Monotherapy Products, H1 2016 32
Number of Products by Stage and Target, H1 2016 34
Number of Products by Stage and Mechanism of Action, H1 2016 36
Number of Products by Stage and Route of Administration, H1 2016 38
Number of Products by Stage and Molecule Type, H1 2016 39
Insomnia Therapeutics - Recent Pipeline Updates, H1 2016 64
Insomnia - Dormant Projects, H1 2016 75
Insomnia - Dormant Projects (Contd..1), H1 2016 76
Insomnia - Dormant Projects (Contd..2), H1 2016 77
Insomnia - Discontinued Products, H1 2016 78
Insomnia - Discontinued Products (Contd..1), H1 2016 79

List of Figures
Number of Products under Development for Insomnia, H1 2016 10
Number of Products under Development for Insomnia - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Number of Products under Investigation by Universities/Institutes, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 14
Comparative Analysis by Clinical Stage Development, H1 2016 15
Comparative Analysis by Early Stage Products, H1 2016 16
Assessment by Monotherapy Products, H1 2016 32
Number of Products by Top 10 Targets, H1 2016 33
Number of Products by Stage and Top 10 Targets, H1 2016 33
Number of Products by Top 10 Mechanism of Actions, H1 2016 35
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 35
Number of Products by Routes of Administration, H1 2016 37
Number of Products by Stage and Routes of Administration, H1 2016 37
Number of Products by Stage and Top 10 Molecule Types, H1 2016 39

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H1 2016

Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H1 2016

  • $ 3 500
  • Company report
  • April 2016
  • by Global Markets Direct

Glucose-Dependent Insulinotropic Receptor (G-Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Glucose-Dependent Insulinotropic Receptor (G-Protein ...

Nociceptin Receptor (Kappa-Type 3 Opioid Receptor or KOR-3 or Orphanin FQ Receptor or OPRL1 or OOR or ORL1) - Pipeline Review, H1 2016

Nociceptin Receptor (Kappa-Type 3 Opioid Receptor or KOR-3 or Orphanin FQ Receptor or OPRL1 or OOR or ORL1) - Pipeline Review, H1 2016

  • $ 3 500
  • Company report
  • April 2016
  • by Global Markets Direct

Nociceptin Receptor (Kappa-Type 3 Opioid Receptor or KOR-3 or Orphanin FQ Receptor or OPRL1 or OOR or ORL1) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Nociceptin Receptor (Kappa-Type ...

Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) - Pipeline Review, H1 2016

Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) - Pipeline Review, H1 2016

  • $ 3 500
  • Company report
  • April 2016
  • by Global Markets Direct

Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.